A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice

Human Molecular Genetics

Volumn 25, Issue 22, 2016, Pages 4920-4938

  Simmons, Danielle A ^a   Belichenko, Nadia P ^a   Ford, Ellen C ^a   Semaan, Sarah ^a   Monbureau, Marie ^a   Aiyaswamy, Sruti ^a   Holman, Cameron M ^a   Condon, Christina ^a   Shamloo, Mehrdad ^a   Massa, Stephen M ^b   Longo, Frank M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 3 METHYLPENTANOIC ACID(2 MORPHOLIN 4YL ETHYL)AMIDE; HUNTINGTIN; ISOLEUCINE; NEUROTROPHIN RECEPTOR P75; PHOSPHOPROTEIN DARPP 32; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; LIGAND; LM11A-31; MORPHOLINE DERIVATIVE; NERVE GROWTH FACTOR RECEPTOR; PROTEIN BINDING; TNFRSF16 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CELL DEGENERATION; CHOLINERGIC NERVE CELL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DENDRITIC SPINE; HIPPOCAMPUS; HUNTINGTON CHOREA; INFLAMMATION; INTERNEURON; MALE; MENTAL DISEASE; MICROGLIA; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; SIGNAL TRANSDUCTION; SURVIVAL; ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; RANDOMIZATION; TRANSGENIC MOUSE;

ANIMALS; DISEASE MODELS, ANIMAL; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; ISOLEUCINE; LIGANDS; MALE; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; MORPHOLINES; PHENOTYPE; PROTEIN BINDING; RANDOM ALLOCATION; RECEPTORS, NERVE GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 85015790906     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddw316     Document Type: Article

References (145)

1. Vonsattel, J., Myers, R., Stevens, T., Ferrante, R., Bird, E. and Richardson, E.J. (1985) Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol., 44, 559-577.
2. Walker, F.O. (2007) Huntington's disease. Lancet, 369, 218-228.
3. Group, HsDCR. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
4. Zuccato, C. and Cattaneo, E. (2007) Role of brain-derived neurotrophic factor in Huntington's disease. Prog. Neurobiol., 81, 294-330.
5. Gharami, K., Xie, Y., An, J.J., Tonegawa, S. and Xu, B. (2008) Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J. Neurochem., 105, 369-379.
6. Reichardt, L.F. (2006) Neurotrophin-regulated signalling pathways. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 361, 1545-1564.
7. Roux, P.P. and Barker, P.A. (2002) Neurotrophin signaling through the p75 neurotrophin receptor. Prog. Neurobiol., 67, 203-233.
8. Coulson, E.J., Reid, K., Murray, S.S., Cheema, S.S. and Bartlett, P.F. (2000) Role of neurotrophin receptor p75NTR in mediating neuronal cell death following injury. Clin. Exp. Pharmacol. Physiol., 27, 537-541.
9. Gentry, J.J., Barker, P.A. and Carter, B.D. (2004) The p75 neurotrophin receptor: multiple interactors and numerous functions. Prog. Brain Res., 146, 25-39.
10. Ibanez, C.F. and Simi, A. (2012) p75 neurotrophin receptor signaling in nervous system injury and degeneration: paradox and opportunity. Trends Neurosci., 35, 431-440.
11. Ma, Q., Yang, J., Li, T., Milner, T.A. and Hempstead, B.L. (2015) Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease. Neurobiol. Dis., 82, 466-477.
12. Brito, V., Puigdellivol, M., Giralt, A., Del Toro, D., Alberch, J. and Gines, S. (2013) Imbalance of p75(NTR)/TrkB protein expression in Huntington's disease: implication for neuroprotective therapies. Cell Death Dis., 4, e595.
13. Fortress, A.M., Buhusi, M., Helke, K.L. and Granholm, A.C. (2011) Cholinergic Degeneration and Alterations in the TrkA and p75NTR Balance as a Result of Pro-NGF Injection into Aged Rats. J. Aging Res., 2011, 460543.
14. Yoon, S.O., Casaccia-Bonnefil, P., Carter, B. and Chao, M.V. (1998) Competitive signaling between TrkA and p75 nerve growth factor receptors determines cell survival. J. Neurosci., 18, 3273-3281.
15. Miguez, A., Garcia-Diaz Barriga, G., Brito, V., Straccia, M., Giralt, A., Gines, S., Canals, J.M. and Alberch, J. (2015) Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation. Hum. Mol. Genet., 24, 4958-4970.
16. Zuccato, C., Marullo, M., Conforti, P., MacDonald, M.E., Tartari, M. and Cattaneo, E. (2008) Systematic assessment of BDNF and its receptor levels in human cortices affected by Huntington's disease. Brain Pathol., 18, 225-238.
17. Plotkin, J.L., Day, M., Peterson, J.D., Xie, Z., Kress, G.J., Rafalovich, I., Kondapalli, J., Gertler, T.S., Flajolet, M., Greengard, P., et al. (2014) Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington's disease. Neuron, 83, 178-188.
18. Simmons, D.A., Belichenko, N.P., Yang, T., Condon, C., Monbureau, M., Shamloo, M., Jing, D., Massa, S.M. and Longo, F.M. (2013) A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. J. Neurosci., 33, 18712-18727.
19. Brito, V., Giralt, A., Enriquez-Barreto, L., Puigdellivol, M., Suelves, N., Zamora-Moratalla, A., Ballesteros, J.J., Martin, E.D., Dominguez-Iturza, N., Morales, M., et al. (2014) Neurotrophin receptor p75(NTR) mediates Huntington's disease-associated synaptic and memory dysfunction. J. Clin. Invest., 124, 4411-4428.
20. Bowles, K.R. and Jones, L. (2014) Kinase signalling in Huntington's disease. J. Huntington's Dis., 3, 89-123.
21. Longo, F.M. and Massa, S.M. (2008) Small molecule modulation of p75 neurotrophin receptor functions. CNS Neurol. Disord. Drug Targets, 7, 63-70.
22. Longo, F.M. and Massa, S.M. (2013) Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease. Nat. Rev. Drug Discov., 12, 507-525.
23. Massa, S.M., Xie, Y., Yang, T., Harrington, A.W., Kim, M.L., Yoon, S.O., Kraemer, R., Moore, L.A., Hempstead, B.L. and Longo, F.M. (2006) Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death. J. Neurosci., 26, 5288-5300.
24. Yang, T., Knowles, J.K., Lu, Q., Zhang, H., Arancio, O., Moore, L.A., Chang, T., Wang, Q., Andreasson, K., Rajadas, J., et al. (2008) Small molecule, non-peptide p75 ligands inhibit Abeta-induced neurodegeneration and synaptic impairment. PLoS One, 3, e3604.
25. Meeker, R.B., Poulton, W., Clary, G., Schriver, M. and Longo, F.M. (2016) Novel p75 neurotrophin receptor ligand stabilizes neuronal calcium, preserves mitochondrial movement and protects against HIV associated neuropathogenesis. Exp. Neurol., 275 Pt 1, 182-198.
26. Knowles, J.K., Rajadas, J., Nguyen, T.V., Yang, T., LeMieux, M.C., Vander Griend, L., Ishikawa, C., Massa, S.M., Wyss-Coray, T. and Longo, F.M. (2009) The p75 neurotrophin receptor promotes amyloid-beta(1-42)-induced neuritic dystrophy in vitro and in vivo. J. Neurosci., 29, 10627-10637.
27. Meeker, R.B., Poulton, W., Feng, W.H., Hudson, L. and Longo, F.M. (2012) Suppression of Immunodeficiency Virus-Associated Neural Damage by the p75 Neurotrophin Receptor Ligand, LM11A-31, in an In Vitro Feline Model. J. Neuroimmune. Pharmacol., 7, 388-400.
28. James, S.E., Burden, H., Burgess, R., Xie, Y., Yang, T., Massa, S.M., Longo, F.M. and Lu, Q. (2008) Anti-cancer drug induced neurotoxicity and identification of Rho pathway signaling modulators as potential neuroprotectants. Neurotoxicology, 29, 605-612.
29. Friesland, A., Weng, Z., Duenas, M., Massa, S.M., Longo, F.M. and Lu, Q. (2014) Amelioration of cisplatin-induced experimental peripheral neuropathy by a small molecule targeting p75 NTR. Neurotoxicology, 45, 81-90.
30. Shi, J., Longo, F.M. and Massa, S.M. (2013) A small molecule p75(NTR) ligand protects neurogenesis after traumatic brain injury. Stem Cells, 31, 2561-2574.
31. Tep, C., Lim, T.H., Ko, P.O., Getahun, S., Ryu, J.C., Goettl, V.M., Massa, S.M., Basso, M., Longo, F.M. and Yoon, S.O. (2013) Oral administration of a small molecule targeted to block proNGF binding to p75 promotes myelin sparing and functional recovery after spinal cord injury. J. Neurosci., 33, 397-410.
32. Knowles, J.K., Simmons, D.A., Nguyen, T.V., Vander Griend, L., Xie, Y., Zhang, H., Yang, T., Pollak, J., Chang, T., Arancio, O., et al. (2013) A small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model. Neurobiol. Aging, 34, 2052-2063.
33. Nguyen, T.V., Shen, L., Vander Griend, L., Quach, L.N., Belichenko, N.P., Saw, N., Yang, T., Shamloo, M., Wyss-Coray, T., Massa, S.M., et al. (2014) Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AbetaPP(L/S) transgenic mice. J. Alzheimer's Dis., 42, 459-483.
34. Simmons, D.A., Knowles, J.K., Belichenko, N.P., Banerjee, G., Finkle, C., Massa, S.M. and Longo, F.M. (2014) A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with midto late-stage disease progression. PLoS One, 9, e102136.
35. Kanning, K.C., Hudson, M., Amieux, P.S., Wiley, J.C., Bothwell, M. and Schecterson, L.C. (2003) Proteolytic processing of the p75 neurotrophin receptor and two homologs generates C-terminal fragments with signaling capability. J. Neurosci., 23, 5425-5436.
36. Ceni, C., Kommaddi, R.P., Thomas, R., Vereker, E., Liu, X., McPherson, P.S., Ritter, B. and Barker, P.A. (2010) The p75NTR intracellular domain generated by neurotrophininduced receptor cleavage potentiates Trk signaling. J. Cell Sci., 123, 2299-2307.
37. Skeldal, S., Matusica, D., Nykjaer, A. and Coulson, E.J. (2011) Proteolytic processing of the p75 neurotrophin receptor: A prerequisite for signalling?: Neuronal life, growth and death signalling are crucially regulated by intra-membrane proteolysis and trafficking of p75(NTR). Bioessays, 33, 614-625.
38. Vicario, A., Kisiswa, L., Tann, J.Y., Kelly, C.E. and Ibanez, C.F. (2015) Neuron-type-specific signaling by the p75NTR death receptor is regulated by differential proteolytic cleavage. J. Cell Sci., 128, 1507-1517.
39. Roux, P.P., Bhakar, A.L., Kennedy, T.E. and Barker, P.A. (2001) The p75 neurotrophin receptor activates Akt (protein kinase B) through a phosphatidylinositol 3-kinase-dependent pathway. J. Biol. Chem., 276, 23097-23104.
40. Colin, E., Regulier, E., Perrin, V., Durr, A., Brice, A., Aebischer, P., Deglon, N., Humbert, S. and Saudou, F. (2005) Akt is altered in an animal model of Huntington's disease and in patients. Eur. J. Neurosci., 21, 1478-1488.
41. Fan, J., Gladding, C.M., Wang, L., Zhang, L.Y., Kaufman, A.M., Milnerwood, A.J. and Raymond, L.A. (2012) P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease. Neurobiol. Dis., 45, 999-1009.
42. Gianfriddo, M., Melani, A., Turchi, D., Giovannini, M.G. and Pedata, F. (2004) Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow. Neurobiol. Dis., 17, 77-88.
43. Taylor, D.M., Moser, R., Regulier, E., Breuillaud, L., Dixon, M., Beesen, A.A., Elliston, L., Silva Santos Mde, F., Kim, J., Jones, L., et al. (2013) MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition. J. Neurosci., 33, 2313-2325.
44. Mattson, M.P. and Meffert, M.K. (2006) Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ., 13, 852-860.
45. Khoshnan, A., Ko, J., Watkin, E.E., Paige, L.A., Reinhart, P.H. and Patterson, P.H. (2004) Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J. Neurosci., 24, 7999-8008.
46. Trager, U., Andre, R., Lahiri, N., Magnusson-Lind, A., Weiss, A., Grueninger, S., McKinnon, C., Sirinathsinghji, E., Kahlon, S., Pfister, E.L., et al. (2014) HTT-lowering reverses Huntington's disease immune dysfunction caused by NFkappaB pathway dysregulation. Brain, 137, 819-833.
47. Hayden, M.S. and Ghosh, S. (2012) NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev., 26, 203-234.
48. Huxford, T., Huang, D.B., Malek, S. and Ghosh, G. (1998) The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell, 95, 759-770.
49. Khoshnan, A. and Patterson, P.H. (2011) The role of IkappaB kinase complex in the neurobiology of Huntington's disease. Neurobiol. Dis., 43, 305-311.
50. Yamashita, T., Tucker, K.L. and Barde, Y.A. (1999) Neurotrophin binding to the p75 receptor modulates Rho activity and axonal outgrowth. Neuron, 24, 585-593.
51. Yamashita, T. and Tohyama, M. (2003) The p75 receptor acts as a displacement factor that releases Rho from Rho-GDI. Nat. Neurosci., 6, 461-467.
52. Bauer, P.O., Wong, H.K., Oyama, F., Goswami, A., Okuno, M., Kino, Y., Miyazaki, H. and Nukina, N. (2009) Inhibition of Rho kinases enhances the degradation of mutant huntingtin. J. Biol. Chem., 284, 13153-13164.
53. Li, M., Huang, Y., Ma, A.A., Lin, E. and Diamond, M.I. (2009) Y-27632 improves rotarod performance and reduces huntingtin levels in R6/2 mice. Neurobiol. Dis., 36, 413-420.
54. Narayanan, K.L., Chopra, V., Rosas, H.D., Malarick, K. and Hersch, S. (2015) Rho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington's Disease. Mol. Neurobiol., 53, 2132-2140.
55. Song, W., Volosin, M., Cragnolini, A.B., Hempstead, B.L. and Friedman, W.J. (2010) ProNGF induces PTEN via p75NTR to suppress Trk-mediated survival signaling in brain neurons. J. Neurosci., 30, 15608-15615.
56. Yang, S. and Kim, H.M. (2012) The RhoA-ROCK-PTEN pathway as a molecular switch for anchorage dependent cell behavior. Biomaterials, 33, 2902-2915.
57. Koth, A.P., Oliveira, B.R., Parfitt, G.M., Buonocore Jde, Q. and Barros, D.M. (2014) Participation of group I p21-activated kinases in neuroplasticity. J. Physiol. Paris, 108, 270-277.
58. Rex, C.S., Chen, L.Y., Sharma, A., Liu, J., Babayan, A.H., Gall, C.M. and Lynch, G. (2009) Different Rho GTPase-dependent signaling pathways initiate sequential steps in the consolidation of long-term potentiation. J. Cell Biol., 186, 85-97.
59. Schurmann, A., Mooney, A.F., Sanders, L.C., Sells, M.A., Wang, H.G., Reed, J.C. and Bokoch, G.M. (2000) p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol. Cell. Biol., 20, 453-461.
60. DiFiglia, M., Sapp, E., Chase, K., Davies, S., Bates, G., Vonsattel, J. and Aronin, N. (1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science, 277, 1990-1993.
61. Zuccato, C., Valenza, M. and Cattaneo, E. (2010) Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol.Rev., 90, 905-981.
62. Pouladi, M.A., Morton, A.J. and Hayden, M.R. (2013) Choosing an animal model for the study of Huntington's disease. Nat. Rev. Neurosci., 14, 708-721.
63. Gray, M., Shirasaki, D.I., Cepeda, C., Andre, V.M., Wilburn, B., Lu, X.H., Tao, J., Yamazaki, I., Li, S.H., Sun, Y.E., et al. (2008) Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci., 28, 6182-6195.
64. Pouladi, M.A., Stanek, L.M., Xie, Y., Franciosi, S., Southwell, A.L., Deng, Y., Butland, S., Zhang, W., Cheng, S.H., Shihabuddin, L.S., et al. (2012) Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum. Mol.Genet., 21, 2219-2232.
65. Bibb, J.A., Yan, Z., Svenningsson, P., Snyder, G.L., Pieribone, V.A., Horiuchi, A., Nairn, A.C., Messer, A. and Greengard, P. (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl. Acad. Sci. U. S. A, 97, 6809-6814.
66. Bogush, A., Pedrini, S., Pelta-Heller, J., Chan, T., Yang, Q., Mao, Z., Sluzas, E., Gieringer, T. and Ehrlich, M.E. (2007) AKT and CDK5/p35 mediate brain-derived neurotrophic factor induction of DARPP-32 in medium size spiny neurons in vitro. J. Biol. Chem., 282, 7352-7359.
67. van Dellen, A., Welch, J., Dixon, R.M., Cordery, P., York, D., Styles, P., Blakemore, C. and Hannan, A.J. (2000) NAcetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport, 11, 3751-3757.
68. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S., et al. (1996) Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell, 87, 493-506.
69. Ferrante, R.J., Kowall, N.W., Beal, M.F., Richardson, E.P., Jr., Bird, E.D. and Martin, J.B. (1985) Selective sparing of a class of striatal neurons in Huntington's disease. Science, 230, 561-563.
70. Ferrante, R.J., Beal, M.F., Kowall, N.W., Richardson, E.P., Jr. and Martin, J.B. (1987) Sparing of acetylcholinesterasecontaining striatal neurons in Huntington's disease. Brain Res., 411, 162-166.
71. Cicchetti, F., Prensa, L., Wu, Y. and Parent, A. (2000) Chemical anatomy of striatal interneurons in normal individuals and in patients with Huntington's disease. Brain Res. Brain Res. Rev., 34, 80-101.
72. Holley, S.M., Joshi, P.R., Parievsky, A., Galvan, L., Chen, J.Y., Fisher, Y.E., Huynh, M.N., Cepeda, C. and Levine, M.S. (2015) Enhanced GABAergic Inputs Contribute to Functional Alterations of Cholinergic Interneurons in the R6/2 Mouse Model of Huntington's Disease. eNeuro, 2, pii: e0008.
73. Deng, Y.P. and Reiner, A. (2016) Cholinergic interneurons in the Q140 knock-in mouse model of Huntington's disease: Reductions in dendritic branching and thalamostriatal input. J Comp. Neurol., Epub ahead of print. doi: 10.1002/cne.24013.
74. Meade, C., Deng, Y., Fusco, F., Del Mar, N., Hersch, S., Goldowitz, D. and Reiner, A. (2002) Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic mice. J. Comp. Neurol., 449, 241-269.
75. Kosinski, C.M., Cha, J.H., Young, A.B., Mangiarini, L., Bates, G., Schiefer, J. and Schwarz, M. (1999) Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice. Neuroreport, 10, 3891-3896.
76. Farrar, A.M., Callahan, J.W. and Abercrombie, E.D. (2011) Reduced striatal acetylcholine efflux in the R6/2 mouse model of Huntington's disease: an examination of the role of altered inhibitory and excitatory mechanisms. Exp. Neurol., 232, 119-125.
77. Smith, R., Chung, H., Rundquist, S., Maat-Schieman, M.L., Colgan, L., Englund, E., Liu, Y.J., Roos, R.A., Faull, R.L., Brundin, P., et al. (2006) Cholinergic neuronal defect without cell loss in Huntington's disease. Hum. Mol. Genet., 15, 3119-3131.
78. Vetter, J.M., Jehle, T., Heinemeyer, J., Franz, P., Behrens, P.F., Jackisch, R., Landwehrmeyer, G.B. and Feuerstein, T.J. (2003) Mice transgenic for exon 1 of Huntington's disease: properties of cholinergic and dopaminergic pre-synaptic function in the striatum. J. Neurochem., 85, 1054-1063.
79. Picconi, B., Passino, E., Sgobio, C., Bonsi, P., Barone, I., Ghiglieri, V., Pisani, A., Bernardi, G., Ammassari-Teule, M. and Calabresi, P. (2006) Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol. Dis., 22, 143-152.
80. Jones, L. and Hughes, A. (2011) Pathogenic mechanisms in Huntington's disease. Int. Rev. Neurobiol., 98, 373-418.
81. Parsons, M.P. and Raymond, L.A. (2014) Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron, 82, 279-293.
82. Imai, Y., Ibata, I., Ito, D., Ohsawa, K. and Kohsaka, S. (1996) A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem. Biophys. Res. Commun., 224, 855-862.
83. Ito, D., Imai, Y., Ohsawa, K., Nakajima, K., Fukuuchi, Y. and Kohsaka, S. (1998) Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res. Mol. Brain Res., 57, 1-9.
84. Ridley, A., Paterson, H., Johnston, C., Diekmann, D. and Hall, A. (1992) The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell, 70, 401-410.
85. Simmons, D.A., Casale, M., Alcon, B., Pham, N., Narayan, N. and Lynch, G. (2007) Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease. Glia, 55, 1074-1084.
86. Wacker, J.L., Huang, S.Y., Steele, A.D., Aron, R., Lotz, G.P., Nguyen, Q., Giorgini, F., Roberson, E.D., Lindquist, S., Masliah, E., et al. (2009) Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease. J. Neurosci., 29, 9104-9114.
87. Franciosi, S., Ryu, J.K., Shim, Y., Hill, A., Connolly, C., Hayden, M.R., McLarnon, J.G. and Leavitt, B.R. (2012) Agedependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol. Dis., 45, 438-449.
88. Mantovani, S., Gordon, R., Li, R., Christie, D.C., Kumar, V. and Woodruff, T.M. (2016) Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice. Hum. Mol. Genet., 25, 1780-1791.
89. Crotti, A. and Glass, C.K. (2015) The choreography of neuroinflammation in Huntington's disease. Trends Immunol., 36, 364-373.
90. Ferrante, R.J., Kowall, N.W. and Richardson, E.P. Jr. (1991) Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J. Neurosci., 11, 3877-3887.
91. Graveland, G., Williams, R. and DiFiglia, M. (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science, 227, 770-773.
92. Heck, N., Betuing, S., Vanhoutte, P. and Caboche, J. (2012) A deconvolution method to improve automated 3D-analysis of dendritic spines: application to a mouse model of Huntington's disease. Brain Struct. Funct., 217, 421-434.
93. Klapstein, G.J., Fisher, R.S., Zanjani, H., Cepeda, C., Jokel, E.S., Chesselet, M.F. and Levine, M.S. (2001) Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J. Neurophysiol., 86, 2667-2677.
94. Rocher, A.B., Gubellini, P., Merienne, N., Boussicault, L., Petit, F., Gipchtein, P., Jan, C., Hantraye, P., Brouillet, E. and Bonvento, G. (2016) Synaptic scaling up in medium spiny neurons of aged BACHD mice: A slow-progression model of Huntington's disease. Neurobiol. Dis., 86, 131-139.
95. Dougherty, K.D. and Milner, T.A. (1999) p75NTR immunoreactivity in the rat dentate gyrus is mostly within presynaptic profiles but is also found in some astrocytic and postsynaptic profiles. J. Comp. Neurol., 407, 77-91.
96. Woo, N.H., Teng, H.K., Siao, C.J., Chiaruttini, C., Pang, P.T., Milner, T.A., Hempstead, B.L. and Lu, B. (2005) Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat. Neurosci., 8, 1069-1077.
97. Zagrebelsky, M., Holz, A., Dechant, G., Barde, Y.A., Bonhoeffer, T. and Korte, M. (2005) The p75 neurotrophin receptor negatively modulates dendrite complexity and spine density in hippocampal neurons. J. Neurosci., 25, 9989-9999.
98. Bolivar, V.J., Manley, K. and Messer, A. (2003) Exploratory activity and fear conditioning abnormalities develop early in R6/2 Huntington's disease transgenic mice. Behav. Neurosci., 117, 1233-1242.
99. Carter, R., Lione, L., Humby, T., Mangiarini, L., Mahal, A., Bates, G., Dunnett, S. and Morton, A. (1999) Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J. Neurosci., 19, 3248-3257.
100. Hickey, M.A., Gallant, K., Gross, G.G., Levine, M.S. and Chesselet, M.F. (2005) Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing. Neurobiol. Dis., 20, 1-11.
101. Menalled, L., El-Khodor, B.F., Patry, M., Suarez-Farinas, M., Orenstein, S.J., Zahasky, B., Leahy, C., Wheeler, V., Yang, X.W., MacDonald, M., et al. (2009) Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis., 35, 319-336.
102. Casaca-Carreira, J., Temel, Y., van Zelst, M. and Jahanshahi, A. (2015) Coexistence of Gait Disturbances and Chorea in Experimental Huntington's Disease. Behav. Neurol., 2015, 970204.
103. Abada, Y.S., Schreiber, R. and Ellenbroek, B. (2012) Motor, emotional and cognitive deficits in adult BACHD mice: A model for Huntington's disease. Behav. Brain Res., 238, 243-251.
104. Grimbergen, Y.A., Knol, M.J., Bloem, B.R., Kremer, B.P., Roos, R.A. and Munneke, M. (2008) Falls and gait disturbances in Huntington's disease. Mov. Disord., 23, 970-976.
105. Koller, W.C. and Trimble, J. (1985) The gait abnormality of Huntington's disease. Neurology, 35, 1450-1454.
106. Shu, Y.H., Lu, X.M., Wei, J.X., Xiao, L. and Wang, Y.T. (2015) Update on the role of p75NTR in neurological disorders: A novel therapeutic target. Biomed. Pharmacother., 76, 17-23.
107. Dechant, G. and Barde, Y.A. (2002) The neurotrophin receptor p75(NTR): novel functions and implications for diseases of the nervous system. Nat. Neurosci., 5, 1131-1136.
108. Meeker, R.B. and Williams, K.S. (2015) The p75 neurotrophin receptor: at the crossroad of neural repair and death. Neural Regen. Res., 10, 721-725.
109. Frade, J.M. (2005) Nuclear translocation of the p75 neurotrophin receptor cytoplasmic domain in response to neurotrophin binding. J. Neurosci., 25, 1407-1411.
110. Jung, K.M., Tan, S., Landman, N., Petrova, K., Murray, S., Lewis, R., Kim, P.K., Kim, D.S., Ryu, S.H., Chao, M.V., et al. (2003) Regulated intramembrane proteolysis of the p75 neurotrophin receptor modulates its association with the TrkA receptor. J. Biol. Chem., 278, 42161-42169.
111. Humbert, S., Bryson, E.A., Cordelieres, F.P., Connors, N.C., Datta, S.R., Finkbeiner, S., Greenberg, M.E. and Saudou, F. (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell, 2, 831-837.
112. Rangone, H., Pardo, R., Colin, E., Girault, J.A., Saudou, F. and Humbert, S. (2005) Phosphorylation of arfaptin 2 at Ser260 by Akt Inhibits PolyQ-huntingtin-induced toxicity by rescuing proteasome impairment. J. Biol. Chem., 280, 22021-22028.
113. Zala, D., Colin, E., Rangone, H., Liot, G., Humbert, S. and Saudou, F. (2008) Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum. Mol. Genet., 17, 3837-3846.
114. Hensel, N., Rademacher, S. and Claus, P. (2015) Chatting with the neighbors: crosstalk between Rho-kinase (ROCK) and other signaling pathways for treatment of neurological disorders. Front. Neurosci., 9, 198.
115. Bauer, P.O. and Nukina, N. (2009) Enhanced degradation of mutant huntingtin by rho kinase inhibition is mediated through activation of proteasome and macroautophagy. Autophagy, 5, 747-748.
116. Shao, J., Welch, W.J., Diprospero, N.A. and Diamond, M.I. (2008) Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation. Mol. Cell. Cell. Biol., 28, 5196-5208.
117. Perrin, V., Dufour, N., Raoul, C., Hassig, R., Brouillet, E., Aebischer, P., Luthi-Carter, R. and Deglon, N. (2009) Implication of the JNK pathway in a rat model of Huntington's disease. Exp. Neurol., 215, 191-200.
118. Govek, E., Newey, S. and Van Aelst, L. (2005) The role of the Rho GTPases in neuronal development. Genes Dev., 19, 1-49.
119. Nakayama, A.Y., Harms, M.B. and Luo, L. (2000) Small GTPases Rac and Rho in the maintenance of dendritic spines and branches in hippocampal pyramidal neurons. J. Neurosci., 20, 5329-5338.
120. Zhang, H., Petit, G.H., Gaughwin, P.M., Hansen, C., Ranganathan, S., Zuo, X., Smith, R., Roybon, L., Brundin, P., Mobley, W.C., et al. (2013) NGF rescues hippocampal cholinergic neuronal markers, restores neurogenesis, and improves the spatial working memory in a mouse model of Huntington's Disease. J. Huntington's Dis., 2, 69-82.
121. Chopra, V., Fox, J.H., Lieberman, G., Dorsey, K., Matson, W., Waldmeier, P., Housman, D.E., Kazantsev, A., Young, A.B. and Hersch, S. (2007) A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc. Natl Acad. Sci. U. S. A, 104, 16685-16689.
122. Dedeoglu, A., Kubilus, J.K., Jeitner, T.M., Matson, S.A., Bogdanov, M., Kowall, N.W., Matson, W.R., Cooper, A.J., Ratan, R.R., Beal, M.F., et al. (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J. Neurosci., 22, 8942-8950.
123. Duan, W., Guo, Z., Jiang, H., Ware, M., Li, X. and Mattson, M. (2003) Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc. Natl. Acad. Sci. U. S. A, 100, 2911-2916.
124. Ferrante, R.J., Andreassen, O.A., Dedeoglu, A., Ferrante, K.L., Jenkins, B.G., Hersch, S.M. and Beal, M.F. (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci., 22, 1592-1599.
125. Yamamoto, A., Lucas, J.J. and Hen, R. (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell, 101, 57-66.
126. Bokoch, G.M. (2003) Biology of the p21-activated kinases. Annu. Rev. Biochem., 72, 743-781.
127. Penzes, P. and Cahill, M.E. (2012) Deconstructing signal transduction pathways that regulate the actin cytoskeleton in dendritic spines. Cytoskeleton, 69, 426-441.
128. Penzes, P. and Rafalovich, I. (2012) Regulation of the actin cytoskeleton in dendritic spines. Adv. Exp. Med.Biol., 970, 81-95.
129. Majumdar, D., Nebhan, C.A., Hu, L., Anderson, B. and Webb, D.J. (2011) An APPL1/Akt signaling complex regulates dendritic spine and synapse formation in hippocampal neurons. Mol. Cell. Neurosci., 46, 633-644.
130. Tashiro, A. and Yuste, R. (2008) Role of Rho GTPases in the morphogenesis and motility of dendritic spines. Methods Enzymol., 439, 285-302.
131. Hong, S.L., Cossyleon, D., Hussain, W.A., Walker, L.J., Barton, S.J. and Rebec, G.V. (2012) Dysfunctional behavioral modulation of corticostriatal communication in the R6/2 mouse model of Huntington's disease. PLoS One, 7, e47026.
132. Aosaki, T., Graybiel, A.M. and Kimura, M. (1994) Effect of the nigrostriatal dopamine system on acquired neural responses in the striatum of behaving monkeys. Science, 265, 412-415.
133. Chen, J.Y., Wang, E.A., Cepeda, C. and Levine, M.S. (2013) Dopamine imbalance in Huntington's disease: a mechanism for the lack of behavioral flexibility. Front. Neurosci., 7, 114.
134. Lawrence, A., Hodges, J., Rosser, A., Kershaw, A., French-Constant, C., Rubinsztein, D. and Robbins, T. and BJ, S. (1998) Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain Pathol., 121, 1329-1341.
135. Lawrence, A.D., Sahakian, B.J., Hodges, J.R., Rosser, A.E., Lange, K.W. and Robbins, T.W. (1996) Executive and mnemonic functions in early Huntington's disease. Brain, 119, 1633-1645.
136. Rao, A.K., Muratori, L., Louis, E.D., Moskowitz, C.B. and Marder, K.S. (2008) Spectrum of gait impairments in presymptomatic and symptomatic Huntington's disease. Mov. Disord., 23, 1100-1107.
137. Bylsma, F.W., Rothlind, J., Hall, M.R., Folstein, S.E. and Brandt, J. (1993) Assessment of adaptive functioning in Huntington's disease. Mov. Disord., 8, 183-190.
138. Marder, K., Zhao, H., Myers, R.H., Cudkowicz, M., Kayson, E., Kieburtz, K., Orme, C., Paulsen, J., Penney, J.B., Jr., Siemers, E., et al. (2000) Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology, 54, 452-458.
139. Wheelock, V.L., Tempkin, T., Marder, K., Nance, M., Myers, R.H., Zhao, H., Kayson, E., Orme, C., Shoulson, I. and Huntington Study, G. (2003) Predictors of nursing home placement in Huntington disease. Neurology, 60, 998-1001.
140. Simmons, D.A., Mehta, R.A., Lauterborn, J.C., Gall, C.M. and Lynch, G. (2011) Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice. Neurobiol. Dis., 41, 436-444.
141. Balci, F., Oakeshott, S., Shamy, J.L., El-Khodor, B.F., Filippov, I., Mushlin, R., Port, R., Connor, D., Paintdakhi, A., Menalled, L., et al. (2013) High-Throughput Automated Phenotyping of Two Genetic Mouse Models of Huntington's Disease. PLoS Currents, 5, doi: 10.1371/currents.hd.124aa0d16753f88215776fba102ceb29.
142. Rudenko, O., Tkach, V., Berezin, V. and Bock, E. (2009) Detection of early behavioral markers of Huntington's disease in R6/2 mice employing an automated social home cage. Behav. Brain Res., 203, 188-199.
143. Franklin, K. and Paxinos, G. (2008) The Mouse Brain in Stereotaxic Coordinates. Elsevier Inc., New York.
144. Lerner, R.P., Trejo Martinez Ldel, C., Zhu, C., Chesselet, M.F. and Hickey, M.A. (2012) Striatal atrophy and dendritic alterations in a knock-in mouse model of Huntington's disease. Brain Res. Bull., 87, 571-578.
145. Bourne, J.N. and Harris, K.M. (2008) Balancing structure and function at hippocampal dendritic spines. Annu. Rev. Neurosci., 31, 47-67.